Implications of maturation for viral gene delivery to skeletal muscle

[1]  L. Kunkel,et al.  The fate of individual myoblasts after transplantation into muscles of DMD patients , 1997, Nature Medicine.

[2]  Simon C Watkins,et al.  Gene transfer to muscle using herpes simplex virus-based vectors , 1997, Neuromuscular Disorders.

[3]  I. Kovesdi,et al.  Myoblast-Mediated Ex Vivo Gene Transfer to Mature Muscle , 1997 .

[4]  Philip R. Johnson,et al.  Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. , 1997, Human gene therapy.

[5]  R. Cull.  Clinical neurophysiology by Jasper R. Daube, 1996, 533 pp. A Davis Company, Philadelphia, ISBN 0-8036-0073-9, £135.00 , 1997, Neuromuscular Disorders.

[6]  Simon C Watkins,et al.  LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector. , 1997, Human gene therapy.

[7]  Simon C Watkins,et al.  Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. , 1997, Human gene therapy.

[8]  Simon C Watkins,et al.  The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers , 1996, Journal of virology.

[9]  D. Brough,et al.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types , 1996, Nature Biotechnology.

[10]  K. Campbell,et al.  In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. , 1996, Gene therapy.

[11]  R. Samulski,et al.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.

[12]  R. Ramakrishnan,et al.  Replication-defective herpes simplex virus vectors for gene transfer in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Balice-Gordon,et al.  In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. , 1996, Human gene therapy.

[14]  Hanns Lochmüller,et al.  Impairment of force generation after adenovirus-mediated gene transfer to muscle is alleviated by adenoviral gene inactivation and host CD8+ T cell deficiency. , 1996, Human gene therapy.

[15]  K. Kurachi,et al.  Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. , 1996, Human gene therapy.

[16]  G. Pari,et al.  Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. , 1996, Gene therapy.

[17]  C. Gravel,et al.  Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. , 1996, Human gene therapy.

[18]  M. Grounds,et al.  Rapid death of injected myoblasts in myoblast transfer therapy , 1996, Muscle & nerve.

[19]  J. Chamberlain,et al.  Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. , 1996, Human molecular genetics.

[20]  C. Caskey,et al.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Hanns Lochmüller,et al.  Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. , 1996, Human gene therapy.

[22]  I. Kovesdi,et al.  Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. , 1995, Gene therapy.

[23]  C. Gravel,et al.  FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. , 1995, Human gene therapy.

[24]  R. R. Rice,et al.  Myoblast transfer in the treatment of Duchenne's muscular dystrophy. , 1995, The New England journal of medicine.

[25]  G. Trinchieri,et al.  Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung , 1995, Nature Medicine.

[26]  Hanns Lochmüller,et al.  Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. , 1995, Biochemical and biophysical research communications.

[27]  J. Glorioso,et al.  Herpes simplex virus type 1 vector mediated gene transfer to muscle. , 1995, Gene therapy.

[28]  L. Kedes,et al.  Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. , 1995, The Journal of clinical investigation.

[29]  Hanns Lochmüller,et al.  Differential short-term transduction efficiency of adult versus newborn mouse tissues by adenoviral recombinants. , 1995, Experimental and molecular pathology.

[30]  L. Chao,et al.  Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. , 1995, Hypertension.

[31]  N. Sarvetnick,et al.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Roy,et al.  Successful myoblast allotransplantation in mdx mice using rapamycin. , 1995, Transplantation.

[33]  L. Chao,et al.  Intramuscular Delivery of Rat Kallikrein-binding Protein Gene Reverses Hypotension in Transgenic Mice Expressing Human Tissue Kallikrein (*) , 1995, The Journal of Biological Chemistry.

[34]  R. Roy,et al.  Very efficient myoblast allotransplantation in mice under FK506 immunosuppression , 1994, Muscle & nerve.

[35]  L. Kedes,et al.  Persistent erythropoiesis by myoblast transfer of erythropoietin cDNA. , 1994, Human gene therapy.

[36]  T. Friedmann,et al.  Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function , 1994, Journal of virology.

[37]  Hanns Lochmüller,et al.  Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. , 1994, Gene therapy.

[38]  G. Acsadi,et al.  Gene transfer into skeletal muscles by isogenic myoblasts. , 1994, Human gene therapy.

[39]  J. Wilson,et al.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Engvall,et al.  Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Campbell,et al.  Deficiency of merosin in dystrophic dy mice and genetic linkage of laminin M chain gene to dy locus. , 1994, The Journal of biological chemistry.

[42]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Acsadi,et al.  A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. , 1994, Human molecular genetics.

[44]  M. Noble,et al.  Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. , 1994, Developmental biology.

[45]  J. Wolff,et al.  Pharmacological enhancement of in vivo foreign gene expression in muscle. , 1994, Gene therapy.

[46]  B. Demeneix,et al.  Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. , 1993, Human gene therapy.

[47]  P. Tonali,et al.  Retroviral vector-mediated gene transfer into human primary myogenic cells leads to expression in muscle fibers in vivo. , 1993, Human gene therapy.

[48]  B. Trapnell,et al.  Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice , 1993, Nature Genetics.

[49]  G. Acsadi,et al.  Invited Review. The potential for gene therapy in duchenne muscular dystrophy and other genetic muscle diseases , 1993, Muscle & nerve.

[50]  M. Perricaudet,et al.  Long–term correction of mouse dystrophic degeneration by adenovirus–mediated transfer of a minidystrophin gene , 1993, Nature genetics.

[51]  George Karpati,et al.  Myoblast transfer in duchenne muscular dystrophy , 1993, Annals of neurology.

[52]  C. Ownby,et al.  Cardiotoxin 1 from cobra (Naja naja atra) venom causes necrosis of skeletal muscle in vivo. , 1993, Toxicon : official journal of the International Society on Toxinology.

[53]  F. Walsh,et al.  Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. , 1993, Human molecular genetics.

[54]  J. Bouchard,et al.  Results of a Triple Blind Clinical Study of Myoblast Transplantations without Immunosuppressive Treatment in Young Boys with Duchenne Muscular Dystrophy , 1993, Cell transplantation.

[55]  P. Briand,et al.  Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice , 1993, Nature.

[56]  C. Richards,et al.  Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions. , 1992, Transplantation proceedings.

[57]  R. Naviaux,et al.  Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[58]  T. Friedmann,et al.  Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1 , 1992, Journal of virology.

[59]  J. Bouchard,et al.  Human myoblast transplantation: Preliminary results of 4 cases , 1992, Muscle & nerve.

[60]  K. Kurachi,et al.  Expression of human factor IX in mice after injection of genetically modified myoblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[61]  H. Blau,et al.  Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation , 1992, Nature.

[62]  J. Mandel,et al.  Adenovirus as an expression vector in muscle cells in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[63]  K. Davies,et al.  Retroviral‐mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro , 1992, FEBS letters.

[64]  J. Leiden,et al.  Systemic delivery of recombinant proteins by genetically modified myoblasts. , 1991, Science.

[65]  H. Blau,et al.  Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. , 1991, Science.

[66]  O. Danos,et al.  Retroviral-mediated gene transfer into hepatocytes in vivo. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[67]  K. Davies,et al.  Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs , 1991, Nature.

[68]  E. Hoffman,et al.  Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse , 1990, The Journal of cell biology.

[69]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[70]  F. Booth,et al.  Stable incorporation of a bacterial gene into adult rat skeletal muscle in vivo. , 1990, The American journal of physiology.

[71]  P. Yurchenco,et al.  Assembly of Basement Membranes a , 1990, Annals of the New York Academy of Sciences.

[72]  J. Mira,et al.  Myosin isoform transitions in regeneration of fast and slow muscles during postnatal development of the rat. , 1989, Developmental biology.

[73]  Y. Pouliot,et al.  Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. , 1989, The American journal of pathology.

[74]  E A Barnard,et al.  The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. , 1989, Science.

[75]  L. Kunkel,et al.  Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts , 1989, Nature.

[76]  Simon C Watkins,et al.  Immunoelectron microscopic localization of dystrophin in myofibres , 1988, Nature.

[77]  Wagner Ek.  The replication of herpes viruses. , 1974 .

[78]  R. Horne,et al.  The icosahedral form of an adenovirus , 1959 .

[79]  S. Kochanek,et al.  Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles , 1998, Gene Therapy.

[80]  S. Kochanek,et al.  Floyd, S.S. Jr. et al. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther. 5, 19-30 , 1998 .

[81]  M. Baru,et al.  Retroviral-mediated in vivo gene transfer into muscle cells and synthesis of human factor IX in mice. , 1995, Intervirology.

[82]  M. Grounds,et al.  Rapid death of donor myoblasts after intramuscular injection in myoblast transfer therapy , 1995 .

[83]  A. Picard,et al.  Gene transfer in regenerating muscle. , 1994, Human gene therapy.

[84]  A. d'Albis,et al.  Regeneration of muscles after cardiotoxin injury I. Cytological aspects , 1988, Biology of the cell.

[85]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.